BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Hepatic Encephalopathy Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Herpes Simplex Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Hypercalcemia industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Hyperparathyroidism Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Hypertrophic Scar Treatment industry to provide essential data & information for the targeted readers.

Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today the completion of an interim analysis of its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center.

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.

Forecast to 2030,’ thoroughly examines the Hypokalemia industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Hypovolemic Shock Treatment industry to provide essential data & information for the targeted readers.

PhorMed Inc, a Nevada Corporation (“PhorMed” or the “Company”), is a privately held clinical stage biopharmaceutical company.